ReviewBiomolecules2026
Non-Coding RNAs in Prediabetes Beyond Glycemic Classification: Tissue Regulatory Networks, Progression Risk, and Intervention-Associated Dynamics.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Prediabetes can be readily identified using established glycemic tests, but these measures provide limited information about underlying molecular heterogeneity, future progression to type 2 diabetes mellitus (T2DM), or molecular responses to preventive interventions. This narrative review evaluates whether non-coding RNAs (ncRNAs) may provide complementary information beyond glycemic classification. We integrate evidence on microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), with brief consideration of emerging small ncRNA classes and epitranscriptomic regulation, emphasizing tissue-resolved regulatory crosstalk in skeletal muscle, liver, pancreatic β-cells, and adipose tissue while distinguishing direct human prediabetes evidence from mechanistic findings derived from related metabolic contexts. Circulating and extracellular-vesicle-associated ncRNAs are critically assessed according to diagnostic, prognostic, predictive, and pharmacodynamic functions. Particular attention is given to Diabetes Prevention Program analyses, in which baseline miRNA profiles were associated with incident T2DM and showed an exploratory treatment-by-biomarker interaction, while metformin exposure was associated with longitudinal changes in circulating miRNAs. Current evidence supports ncRNAs primarily as hypothesis-generating tools for mechanistic discovery and as candidate markers for progression risk and intervention-associated molecular dynamics, rather than replacements for established glycemic testing. Prospective validation is required to determine whether ncRNA profiling adds clinically meaningful information beyond conventional risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.